Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Bookmark and Share
Published: 18 Dec 2019
Views: 509
Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Prof Martine Piccart gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the update data from the APHINITY trial which investigated the addition of pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer.

Watch our interview with Prof Martine Piccart here.

Read more about the study here